Left Ventricular Assist Device Thrombosis Treated with Intravenous Tissue Plasminogen Activator in a Patient with COVID-19 Infection

Authors

Simone A. Jarrett, Einstein Medical Center, PhiladelphiaFollow
Jafar Alzubi, Einstein Medical Center, PhiladelphiaFollow
Savalan Babapoor-Farrokhran, Einstein Medical Center, PhiladelphiaFollow
Zaid Ammari, Einstein Medical Center, PhiladelphiaFollow
Mohammad Al-Sarie, Einstein Medical Center, PhiladelphiaFollow
Zachary Port, Einstein Medical Center, PhiladelphiaFollow
Farhan Hasni, Einstein Medical Center, PhiladelphiaFollow
Behnam Bozorgnia, Einstein Medical Center, PhiladelphiaFollow
Raphael Bonita, Einstein Medical Center, PhiladelphiaFollow

Document Type

Case Report

Abstract

Left ventricular assist device (LVAD) implantation is an established treatment for patients with end-stage, systolic heart failure as a bridge to heart transplantation or destination therapy. LVAD pump thrombosis is a life-threatening complication than can be triggered by prothrombotic conditions such as infection. Management of pump thrombosis presents as both a diagnostic and therapeutic challenge that is associated with a high morbidity and mortality. We report a case of pump thrombosis in a patient with a HeartMate II (Abbott Laboratories, Chicago, IL) and coronavirus (COVID-19) infection that was treated successfully with an intravenous thrombolytic, tissue plasminogen activator.

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Recommended Citation

Jarrett, Simone A.; Alzubi, Jafar; Babapoor-Farrokhran, Savalan; Ammari, Zaid; Al-Sarie, Mohammad; Port, Zachary; Hasni, Farhan; Bozorgnia, Behnam; and Bonita, Raphael (2021) "Left Ventricular Assist Device Thrombosis Treated with Intravenous Tissue Plasminogen Activator in a Patient with COVID-19 Infection," The VAD Journal: Vol. 7(1) :e2021716 DOI: https://doi.org/10.11589/vad/e2021716

Available at: https://digitalcommons.library.tmc.edu/vad/vol7/iss1/6

First Page

e2021716